In a high-stakes move set to reshape the biotech landscape, Taiho Pharmaceutical Co. Ltd. announced Monday that it will acquire Swiss biotech firm Araris Biotech AG in a deal worth up to $1.14 billion. The acquisition marks a major leap for Taiho as it bolsters its cancer drug pipeline with Araris’ groundbreaking antibody-drug conjugate (ADC) technology.
Under the agreement, Taiho will pay $400 million upfront at closing, with the possibility of additional milestone-based payments totaling up to $740 million. The acquisition cements the deepening relationship between the two companies, which first established a research collaboration in November 2023.
Araris: A Swiss Powerhouse in ADC Innovation
Araris, a spin-off from the Paul Scherrer Institute in Switzerland, has developed a cutting-edge ADC platform that could redefine precision cancer treatment. ADCs are engineered to selectively deliver potent cytotoxic drugs directly to cancer cells by attaching them to antibodies via specialized linkers, minimizing collateral damage to healthy tissues.
The company is advancing three ADC candidates for hematological and solid tumor treatments, drawing industry-wide attention for its potential to improve efficacy while reducing toxicity.
“Araris’ unique ADC technology represents a quantum leap for the ADC field, potentially offering precise payload delivery of multiple mechanisms of action simultaneously to the tumor, with less toxicity,” said Araris CEO and co-founder Dragan Grabulovski.
By integrating Araris’ expertise, Taiho aims to expand its proprietary small molecule drug discovery platform, Cysteinomix, and accelerate its push into next-generation oncology therapeutics.
